Kymriah Purple Book BLA 125646
- BLA number
- 125646
- Proprietary names
- Kymriah
- Proper names
- tisagenlecleucel
- Applicant
- Novartis Pharmaceuticals Corporation
- Center
- CBER
- First observed release
- 2020-08-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Kymriah | tisagenlecleucel | 351(a) | 0.6 to 6.0 x 10^8 CAR-POSITIVE VIABLE T CELLS | Injection | Intravenous | Bag | Rx | Licensed | 2017-08-30 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2025-12-01 | U | 001 | Kymriah | 351(a) | Rx | Novartis Pharmaceuticals Corporation |
| 2023-07-01 | U | 001 | Kymriah | 351(a) | Rx | Novartis Pharmaceuticals Corporation |
| 2023-03-01 | U | 001 | Kymriah | 351(a) | Rx | Novartis Pharmaceuticals Corporation |
| 2021-09-01 | U | 001 | Kymriah | 351(a) | Rx | Novartis Pharmaceuticals Corporation |
| 2021-05-01 | U | 001 | Kymriah | 351(a) | Rx | Novartis Pharmaceuticals Corporation |
| 2020-08-01 | R | 001 | Kymriah | 351(a) | Rx | Novartis Pharmaceuticals Corporation |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2023-07-01 | 001 | Kymriah | 351(a) | Rx | Licensed | 2017-08-30 |
| 2020-08-01 | 001 | Kymriah | 351(a) | Rx | Licensed | 2017-08-30 |